Zaloguj się

Gotowe bibliografie tematyczne / Digoxin

Spis treści

Artykuły w czasopismach
Rozprawy doktorskie
Książki
Części książek
Streszczenia konferencji

Gotowa bibliografia na temat „Digoxin”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 25 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Digoxin”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Digoxin"

1

Masse, Ève, Michel Germain, Marie-Sophie Lambert, Jacinthe Leclerc, Maude Lavallée, and Julie Méthot. "Analyse descriptive de l’efficacité et de la toxicité de la dose de charge intraveineuse de digoxine à l’Institut universitaire de cardiologie et de pneumologie de Québec–Université Laval." Pharmactuel 58, no. 1 (2025): 13–21. https://doi.org/10.63209/1545.

Pełny tekst źródła

Streszczenie:

Objectifs : Les objectifs de l’étude sont de déterminer la proportion de dose de charge de digoxine par voie intraveineuse associée à un contrôle satisfaisant de la fréquence cardiaque en contexte de fibrillation auriculaire ou de flutter auriculaire, d’identifier les doses de charge suivies d’une digoxinémie et de déterminer les facteurs associés à l’efficacité et à la toxicité de la digoxine. Méthode : Étude rétrospective descriptive de population longitudinale menée entre le 1er mai 2019 et le 1er mai 2023. Les variables comprenaient des données relatives au patient, à la prescription, ains

Style APA, Harvard, Vancouver, ISO itp.

2

Wang, Kai-di, Xiang Ding, Nan Jiang, et al. "Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis." Annals of the Rheumatic Diseases 81, no. 4 (2021): 544–55. http://dx.doi.org/10.1136/annrheumdis-2021-221380.

Pełny tekst źródła

Streszczenie:

ObjectivesDysregulated chondrocyte metabolism is closely associated with the pathogenesis of osteoarthritis (OA). Suppressing chondrocyte catabolism to restore cartilage homeostasis has been extensively explored, whereas far less effort has been invested toward enhancing chondrocyte anabolism. This study aimed to repurpose clinically approved drugs as potential stimulators of chondrocyte anabolism in treating OA.MethodsScreening of a Food and Drug Administration-approved drug library; Assays for examining the chondroprotective effects of digoxin in vitro; Assays for defining the therapeutic ef

Style APA, Harvard, Vancouver, ISO itp.

3

Wermeling, Daniel P., Carinda J. Feild, Deborah A. Smith, Mary H. H. Chandler, G. Dennis Clifton, and Duane A. Boyle. "Effects of Long‐Term Oral Carvedilol on the Steady‐State Pharmacokinetics of Oral Digoxin in Patients With Mild to Moderate Hypertension." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 14, no. 5 (1994): 600–606. http://dx.doi.org/10.1002/j.1875-9114.1994.tb02857.x.

Pełny tekst źródła

Streszczenie:

The effect of multiple oral doses of carvedilol on steady‐state plasma digoxin pharmacokinetics was evaluated in 12 patients with mild to moderate hypertension. Area under the curve (AUC), mean maximum plasma concentration (Cmax), mean time to maximum concentration (Tmax), concentration at 24 hours after the dose (C24), creatinine clearance, renal digoxin clearance, and urinary digoxin excretion were determined after patients took oral digoxin 0.25 mg once/day for 2 weeks. Carvedilol was added to the regimen, and digoxin pharmacokinetics were assessed after 2 weeks of concurrent treatment. The

Style APA, Harvard, Vancouver, ISO itp.

4

Scalese, Michael J., and Dominick J. Salvatore. "Role of Digoxin in Atrial Fibrillation." Journal of Pharmacy Practice 30, no. 4 (2016): 434–40. http://dx.doi.org/10.1177/0897190016642361.

Pełny tekst źródła

Streszczenie:

Since its isolation in the 1930s, digoxin has played a pivotal role in the treatment of cardiac conditions including heart failure and supraventricular tachyarrhythmias. The parasympathomimetic activity makes digoxin a reasonable option for controlling ventricular rate in atrial fibrillation (AF). However, the unique pharmacokinetic properties, electrolyte-dependent effects, and P-glycoprotein drug interactions influence the clinical use of digoxin. In addition, the delayed onset and narrow therapeutic index can make digoxin utilization cumbersome and often necessitates serum drug monitoring.

Style APA, Harvard, Vancouver, ISO itp.

5

Qadhi, Rawabi, Tran Tran, Stefanie Lip, Ogor Team, Linsay Macallum, and Sandosh Padmanabhan. "ASSESSING THE CLINICAL IMPACT OF PROTON PUMP INHIBITOR-DIGOXIN INTERACTIONS: A RETROSPECTIVE COHORT STUDY OF HOSPITALIZATION AND MORTALITY RISK." Journal of Hypertension 42, Suppl 1 (2024): e253-e254. http://dx.doi.org/10.1097/01.hjh.0001022092.07013.e9.

Pełny tekst źródła

Streszczenie:

Objective: Digoxin pharmacokinetics are altered by co-administration of proton pump inhibitors (PPI). This may have adverse clinical consequences given digoxin's narrow therapeutic index. Our aim was to investigate whether there was evidence for the association of digoxin-PPI interactions with early adverse clinical events. Design and method: A retrospective cohort study was conducted using an anonymised extract of linked routinely collected Greater Glasgow and Clyde hospitals data between 01/01/2014 and 31/12/2022. Patients aged 40 years and over when commencing either a PPI or digoxin were c

Style APA, Harvard, Vancouver, ISO itp.

6

Atkins, Clarke E., Patti S. Snyder, Bruce W. Keene, and John E. Rush. "Effects of compensated heart failure on digoxin pharmacokinetics in cats." Journal of the American Veterinary Medical Association 195, no. 7 (1989): 945–50. https://doi.org/10.2460/javma.1989.195.07.945.

Pełny tekst źródła

Streszczenie:

Summary To evaluate the effects of compensated heart failure (hf) on digoxin pharmacokinetic properties in cats, 6 cats with dilated cardiomyopathy were compared with 6 clinically normal (control) cats. Digoxin tablets were administered at a dosage of 0.01 mg/kg of body weight, q 48 h for approximately 10 days, until presumed steady state was reached. Both groups were treated concomitantly with aspirin, furosemide, and a commercial low-salt diet. Retrospectively, control and hf cats were calculated to be at 95% and 97% steady state, respectively. At the time blood samples were collected, hf ca

Style APA, Harvard, Vancouver, ISO itp.

7

Ren, Yulin, Sijin Wu, Joanna E. Burdette, Xiaolin Cheng, and A. Douglas Kinghorn. "Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation." Molecules 26, no. 12 (2021): 3672. http://dx.doi.org/10.3390/molecules26123672.

Pełny tekst źródła

Streszczenie:

Digoxin is a cardiac glycoside long used to treat congestive heart failure and found recently to show antitumor potential. The hydroxy groups connected at the C-12, C-14, and C-3′a positions; the C-17 unsaturated lactone unit; the conformation of the steroid core; and the C-3 saccharide moiety have been demonstrated as being important for digoxin’s cytotoxicity and interactions with Na+/K+-ATPase. The docking profiles for digoxin and several derivatives and Na+/K+-ATPase were investigated; an additional small Asn130 side pocket was revealed, which could be useful in the design of novel digoxin

Style APA, Harvard, Vancouver, ISO itp.

8

Suryoputri, Masita Wulandari, Laksmi Maharani, and Ika Mustikaningtias. "Penyesuaian Dosis Digoxin pada Pasien Gagal Jantung di RSUD Margono Soekardjo Purwokerto." JURNAL ILMU KEFARMASIAN INDONESIA 19, no. 2 (2021): 248. http://dx.doi.org/10.35814/jifi.v19i2.778.

Pełny tekst źródła

Streszczenie:

Tingginya prevalensi penyakit gagal jantung di Indonesia menyebabkan penggunaan obat digoxin semakin meningkat. Digoxin merupakan obat indeks terapi sempit yang perlu dilakukan pemantauan kadar obat dalam darah. Apabila estimasi kadar obat dalam darah tidak sesuai kisaran terapetik maka diperlukan penyesuaian dosis pada pasien, sehingga outcome klinis tercapai dan efek toksik dapat dihindari. Dosis pemeliharaan digoksin oral adalah 0,0625 – 0,125 mg/hari untuk pasien gagal jantung dan diharapkan kadar kisaran terapetik digoksin dalam darah berkisar 0,5-0,9 ng/ml. Tujuan penelitian ini adalah u

Style APA, Harvard, Vancouver, ISO itp.

9

Tuffaha, Haya, Laith Alshoaibi, Aya Al-tarawneh, et al. "Therapeutic drug monitoring of digoxin in Jordanian patients: Comparing saliva versus plasma." Journal of Research in Pharmacy 29, no. 4 (2024): 1485–94. https://doi.org/10.12991/jrespharm.1734554.

Pełny tekst źródła

Streszczenie:

Therapeutic drug monitoring (TDM) is measuring drug concentrations in plasma, serum or blood, to assure that drug concentrations can be maintained within a target range and to make sure the amount of medicine being administered is both safe and effective. TDM is essential to avoid digoxin toxicity due to its narrow therapeutic window (therapeutic levels of digoxin are 0.8-2.0 ng/mL. The toxic level is >2.4 ng/mL). TDM of digoxin is currently performed by plasma sampling, which is an invasive and painful procedure. The aim of the study is to study the pharmacokinetics of digoxin in plasma an

Style APA, Harvard, Vancouver, ISO itp.

10

Cremer, Edivaldo, Almir Conrrado Rodrigues de Lima, Larissa Laila Cassarotti, Gabrielle Rodrigues Munhoz, Romulo Jordão Barbosa Pedrinho, and Roberto Kenji Nakamura Cuman. "Mortalidade de indivíduos idosos cardíacos tratados com digoxina." Revista Recien - Revista Científica de Enfermagem 10, no. 29 (2020): 120–28. http://dx.doi.org/10.24276/rrecien2358-3088.2020.10.29.120-128.

Pełny tekst źródła

Streszczenie:

Objetivou-se descrever as taxas de mortalidade e sobrevida de idosos com insuficiência cardíaca que fizeram uso de digoxina, bem como identificar os fatores de risco associados à mortalidade. Prontuários de pacientes idosos (≥60 anos) atendidos no ambulatório de cardiologia para insuficiência cardíaca e que fizeram uso de digoxina foram triados e selecionados para este estudo retrospectivo. Variáveis sociodemográficas e clínicas foram mensuradas. A sobrevida foi verificada pelas curvas de Kaplan-Meier e teste log-rank. A regressão logística múltipla ajustada foi utilizada para avaliar os poten

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Rozprawy doktorskie na temat "Digoxin"

1

Alexandrovich, Susan K. "Characterization of monoclonal antibodies against digoxin /." Online version of thesis, 1987. http://hdl.handle.net/1850/10681.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Matthewson, Beryl Ellen. "Digoxin-like immunoreactive substances in the neonate." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/28022.

Pełny tekst źródła

Streszczenie:

Digoxin, a steroidal glycoside that inhibits Na⁺/K⁺-ATPase, is the most commonly prescribed cardiac medication in North America. Blood levels of this drug are routinely measured to reduce the risks of toxicity. Reports questioning the specificity of antisera used in radioimmunoassays for serum digoxin measurements began to appear after 1975¹ when plasma from patients with renal failure, not on glycoside therapy, showed false-positive digoxin levels. Since then, digoxin-like immunoreactive substances (DLIS) have been found in sera from patients with hepatic failure, hypertension, pre-eclampsia,

Style APA, Harvard, Vancouver, ISO itp.

3

Hui, James. "Analysis for digoxin and metabolites in serum and digoxin disposition in the elderly with gastrointestinal disease after two oral dosage forms /." The Ohio State University, 1988. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487587604130428.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Hallberg, Pär. "Pharmacogenomics of antihypertensive treatment & clinical pharmacological studies of digoxin treatment /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Cavet, Megan Elizabeth. "Intestinal secretion of organic solutes." Thesis, University of Newcastle Upon Tyne, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318538.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Svensson, Åsa. "Applications of a new logic to old drugs: angiogenesis inhibition in neuroblastoma /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3458.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

BARROS, Isabel Cristina Medeiros. "Monitoração terapêutica das concentrações plásmaticas da digoxina em pacientes com insuficiência cardíaca." Universidade Federal de Goiás, 2008. http://repositorio.bc.ufg.br/tede/handle/tde/1703.

Pełny tekst źródła

Streszczenie:

Made available in DSpace on 2014-07-29T15:29:05Z (GMT). No. of bitstreams: 1 dissertacao isabel cristina.pdf: 549593 bytes, checksum: ff591d0e143ca66263716f60188e9801 (MD5) Previous issue date: 2008-10-27<br>It was investigated the clinical, lab and plasma digoxin concentration profiles in 15 cardiac heart failure (CHF) outpatients of the Cardiac Heart Service of the Goias Federal University Clinical Hospital. It was aimed to know plasma digoxin concentration profile in 15 cardiac heart failure (CHF) outpatients by two analytical methods, taking account clinical, laboratorial, habits, anthro

Style APA, Harvard, Vancouver, ISO itp.

8

Embree, Leanne. "Development of a sensitive, quantitative high-performance liquid chromatographic assay for the measurement of digoxin in patient groups with high levels of digoxin-like immunoreactive substances." Thesis, University of British Columbia, 1989. http://hdl.handle.net/2429/29093.

Pełny tekst źródła

Streszczenie:

Digoxin is the most commonly used digitalis glycoside for the treatment of congestive heart failure and certain disturbances of cardiac rhythm. The low therapeutic index observed for digoxin and the clinical significance of digoxin therapy have necessitated the development of sensitive analytical methods for the quantitation of digoxin in biological samples. Digoxin may be analysed by several methods including immunoassays, chromatographic procedures and various biological and chemical methods. Immunoassays, both radioimmunoassay (RIA) and fluorescence polarization immunoassay (FPIA) procedur

Style APA, Harvard, Vancouver, ISO itp.

9

Hallberg, Pär. "Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment." Doctoral thesis, Uppsala universitet, Institutionen för medicinska vetenskaper, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.

Pełny tekst źródła

Streszczenie:

In Part I we found that the CYP2C9 genotype appears to influence the diastolic blood pressure response to the angiotensin II-receptor antagonist irbesartan in patients with hypertension and left ventricular hypertrophy. Those with the *1/*2 genotype (slower metabolism) responded better than those with the *1/*1 genotype (normal metabolism), likely due to a slower elimination of the drug. We further found that a +9/-9 exon 1 polymorphism of the B2 bradykinin receptor gene – shown to affect mRNA expression - appears to influence the regression of left ventricular mass during therapy with irbesar

Style APA, Harvard, Vancouver, ISO itp.

10

Vetticaden, Santosh John. "Evaluation of Analytical, Pharmacokinetic and Pharmacodynamic Methods for the Study of Digoxin." VCU Scholars Compass, 1985. http://scholarscompass.vcu.edu/etd/5103.

Pełny tekst źródła

Streszczenie:

The primary objective of the research was to investigate the pharmacodynamics of digoxin in dogs. Initially an assay specific for digoxin in the presence of its major metabolites, viz., digoxigenin, digoxigenin mono-digitoxoside, digoxigenin bis-digitoxoside and dihydrodigoxin was developed using HPLC-RIA. Methodology for non-invasive measurement of left ventricular ejection time (LVET) and other systolic time intervals (STI) in beagle dogs were developed. This involved surgery for exteriorization of the carotid artery in the dogs and subsequent measurements of LVET and STI after recovery. STI

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Książki na temat "Digoxin"

1

Buchko, Sandra. The effect of nebulized salbutamol on serum digoxin concentration. Ottawa General Hospital, 1991.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

universitet, Odense, ed. Digoxin interactions: The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. distributed by the Almqvist & Wiksell Periodical Company, 1985.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Klüppel, Arnulf. Untersuchungen zur dosisunabhängigen Pharmakokinetik von Digoxin. [s.n.], 1986.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Bissland, Ted. Death shift: The digoxin murders at "Sick Kids". Bantam, 1985.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Kurup, Ravikumar, and Parameswaran Achutha Kurup. The third element: Actinidic archaea, digoxin, and the biological universe. Nova Science Publishers, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Kurup, Ravikumar. Hypothalamic digoxin, cerebral dominance and brain function in health and diseases. Nova Science Publishers, Inc., 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Joreteg, Torbjörn. Digoxin binding to skeletal muscle: Factors of importance for an activity dependency. [s.n.], 1985.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Stenzel, Joachim. Der Einfluss von Nisoldipin auf die Digoxin- und Digitoxinplasmaspiegel und hämodynamische Effekte. [s.n.], 1987.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Düsseldorf, Universität, ed. Der Einfluss von Digoxin auf die Kernreihenbildung in den Herzmuskelzellen des Schweines. [s.n.], 1987.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Peter, Inge. Dosis-Wirkungsbeziehungen extrakardialer Effekte von Digoxin und Meproscillarin an gesunden Versuchspersonen: (placebokontrollierte Doppelblindstudie). [s.n.], 1985.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Części książek na temat "Digoxin"

1

Gebran, Nicole. "Digoxin." In Textbook of Clinical Pediatrics. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_275.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Beyer, Karl-Heinz. "Digoxin." In Biotransformation der Arzneimittel. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74386-3_107.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Vidal, C., and W. R. Külpmann. "Digoxin." In Springer Reference Medizin. Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_892.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Vidal, C., and W. R. Külpmann. "Digoxin." In Lexikon der Medizinischen Laboratoriumsdiagnostik. Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_892-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Dasgupta, Amitava. "Digoxin." In Handbook of Drug Monitoring Methods. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-031-7_6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Wilson, John Fawcett. "Digoxin." In The Immunoassay Kit Directory. Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_15.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Peter, Helga, and Thomas Penzel. "Digoxin." In Springer Reference Medizin. Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_451-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Chen, Ying, Lan Sun, and Guan-Hua Du. "Digoxin." In Natural Small Molecule Drugs from Plants. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8022-7_8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Schneider, Achim, Günther Schlunck, and Viola Sieber. "Digoxin." In Geburtshilfefibel. Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-97317-8_54.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Peter, Helga, and Thomas Penzel. "Digoxin." In Springer Reference Medizin. Springer Berlin Heidelberg, 2025. https://doi.org/10.1007/978-3-662-65186-5_451.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Digoxin"

1

Martín Santamaría, A., C. Lozano Llano, S. Renedo Martinez, et al. "4CPS-200 Case report: treatment of digoxin intoxication in a haemodialysis patient using anti-digoxin antibodies and plasmapheresis." In 29th EAHP Congress, Copenhagen, Denmark, 12-13-14 March 2025, Person centred pharmacy — Navigating digital health. British Medical Journal Publishing Group, 2025. https://doi.org/10.1136/ejhpharm-2025-eahp.261.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Karthikeyan, Ganesan. "28 Should we be using digoxin in 2018?" In 2nd Asia Pacific Advanced Heart Failure Forum (APAHFF 2018), 16th November 2018, Hong Kong. BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association, 2019. http://dx.doi.org/10.1136/heartasia-2019-apahff.28.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Powell, C., M. Barrett, K. Flynn, D. Meenaghan, and K. McDonald. "54 A year in the life of digoxin." In Irish Cardiac Society 74th Annual Scientific Meeting & AGM, October 12th–14th 2023, Killashee House Hotel, Kildare, Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2023. http://dx.doi.org/10.1136/heartjnl-2023-ics.54.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Granell, C. Liñana, L. Belles Medall, O. Pascual Marmaneu, et al. "PKP-008 Implementation of a monitoring protocol for digoxin." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.436.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Espinosa, James, Darren Finn, and Alan Lucerna. "Case Report and Review: Hawthorne Root Toxicity." In 27th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2023. https://doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.119_2023.

Pełny tekst źródła

Streszczenie:

Here we present the case of a patient who purchased a hawthorn root product, Raiz de Tejocote, for weight loss purposes. The side effect profile seen, including a positive digoxin level, are consistent with hawthorn root. This case reinforces the importance of asking a patient about all medications, including over the internet medications.

Style APA, Harvard, Vancouver, ISO itp.

6

Martínez Simón, JJ, A. Martín Suárez, AM Gómez Pedrero, and M. Pérez Encinas. "5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.456.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Rodríguez Esquíroz, A., C. Leralta González, M. Jiménez Meseguer, et al. "5PSQ-010 Digoxin adjustment: comparative analysis of three pharmacokinetic software." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.237.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Schwegman, A., S. Herasevich, Y. Subat, O. Gajic, and C. Bennett. "Digoxin Use in Patients with Sepsis: A Single-Center Retrospective Cohort Study." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6500.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Magro Vázquez, C., C. González Trigueros, AL Salcedo Mingoarranz, et al. "4CPS-103 Pharmacokinetic interaction study of osimertinib and digoxin: a case report." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.119.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Abbasi, A., A. Nikfarjam, and J. Mohammadnejad. "Simulation of digoxin single molecule detection through resonant frequency shift of a CNT." In 2013 First RSI/ISM International Conference on Robotics and Mechatronics (ICRoM 2013). IEEE, 2013. http://dx.doi.org/10.1109/icrom.2013.6510132.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!